Noninvasive Testing and Surrogate Markers in Invasive Fungal Diseases

George R. Thompson; David R. Boulware; Nathan C. Bahr; Cornelius J. Clancy; Thomas S. Harrison; Carol A. Kauffman; Thuy Le; Marisa H. Miceli; Eleftherios Mylonakis; M. Hong Nguyen; Luis Ostrosky-Zeichner; Thomas F. Patterson; John R. Perfect; Andrej Spec; Dimitrios P. Kontoyiannis; Peter G. Pappas

doi:10.1093/ofid/ofac112

Noninvasive Testing and Surrogate Markers in Invasive Fungal Diseases

George R. Thompson, David R. Boulware, Nathan C. Bahr, Cornelius J. Clancy, Thomas S. Harrison, Carol A. Kauffman, Thuy Le, Marisa H. Miceli, Eleftherios Mylonakis, M. Hong Nguyen, Luis Ostrosky-Zeichner, Thomas F. Patterson, John R. Perfect, Andrej Spec, Dimitrios P. Kontoyiannis, Peter G. Pappas

Houston Methodist

Research output: Contribution to journal › Review article › peer-review

24 Scopus citations

Abstract

Invasive fungal infections continue to increase as at-risk populations expand. The high associated morbidity and mortality with fungal diseases mandate the continued investigation of novel antifungal agents and diagnostic strategies that include surrogate biomarkers. Biologic markers of disease are useful prognostic indicators during clinical care, and their use in place of traditional survival end points may allow for more rapid conduct of clinical trials requiring fewer participants, decreased trial expense, and limited need for long-term follow-up. A number of fungal biomarkers have been developed and extensively evaluated in prospective clinical trials and small series. We examine the evidence for these surrogate biomarkers in this review and provide recommendations for clinicians and regulatory authorities.

Original language	English (US)
Article number	ofac112
Journal	Open Forum Infectious Diseases
Volume	9
Issue number	6
DOIs	https://doi.org/10.1093/ofid/ofac112
State	Published - Jun 1 2022

Keywords

diagnosis
fungal infections
mycology

ASJC Scopus subject areas

Oncology
Infectious Diseases

Access to Document

10.1093/ofid/ofac112

Cite this

Thompson, G. R., Boulware, D. R., Bahr, N. C., Clancy, C. J., Harrison, T. S., Kauffman, C. A., Le, T., Miceli, M. H., Mylonakis, E., Nguyen, M. H., Ostrosky-Zeichner, L., Patterson, T. F., Perfect, J. R., Spec, A., Kontoyiannis, D. P., & Pappas, P. G. (2022). Noninvasive Testing and Surrogate Markers in Invasive Fungal Diseases. Open Forum Infectious Diseases, 9(6), Article ofac112. https://doi.org/10.1093/ofid/ofac112

Thompson, GR, Boulware, DR, Bahr, NC, Clancy, CJ, Harrison, TS, Kauffman, CA, Le, T, Miceli, MH, Mylonakis, E, Nguyen, MH, Ostrosky-Zeichner, L, Patterson, TF, Perfect, JR, Spec, A, Kontoyiannis, DP & Pappas, PG 2022, 'Noninvasive Testing and Surrogate Markers in Invasive Fungal Diseases', Open Forum Infectious Diseases, vol. 9, no. 6, ofac112. https://doi.org/10.1093/ofid/ofac112

@article{e2625cf4d56f4658a4e98e0a5179523a,

title = "Noninvasive Testing and Surrogate Markers in Invasive Fungal Diseases",

abstract = "Invasive fungal infections continue to increase as at-risk populations expand. The high associated morbidity and mortality with fungal diseases mandate the continued investigation of novel antifungal agents and diagnostic strategies that include surrogate biomarkers. Biologic markers of disease are useful prognostic indicators during clinical care, and their use in place of traditional survival end points may allow for more rapid conduct of clinical trials requiring fewer participants, decreased trial expense, and limited need for long-term follow-up. A number of fungal biomarkers have been developed and extensively evaluated in prospective clinical trials and small series. We examine the evidence for these surrogate biomarkers in this review and provide recommendations for clinicians and regulatory authorities.",

keywords = "diagnosis, fungal infections, mycology",

author = "Thompson, {George R.} and Boulware, {David R.} and Bahr, {Nathan C.} and Clancy, {Cornelius J.} and Harrison, {Thomas S.} and Kauffman, {Carol A.} and Thuy Le and Miceli, {Marisa H.} and Eleftherios Mylonakis and Nguyen, {M. Hong} and Luis Ostrosky-Zeichner and Patterson, {Thomas F.} and Perfect, {John R.} and Andrej Spec and Kontoyiannis, {Dimitrios P.} and Pappas, {Peter G.}",

note = "Funding Information: Existing departmental funding and the Burden Family Gift Fund for Coccidioidomycosis Research supported this work. Publisher Copyright: {\textcopyright} 2022 The Author(s).",

year = "2022",

month = jun,

day = "1",

doi = "10.1093/ofid/ofac112",

language = "English (US)",

volume = "9",

journal = "Open Forum Infectious Diseases",

issn = "2328-8957",

publisher = "Oxford University Press",

number = "6",

}

TY - JOUR

T1 - Noninvasive Testing and Surrogate Markers in Invasive Fungal Diseases

AU - Thompson, George R.

AU - Boulware, David R.

AU - Bahr, Nathan C.

AU - Clancy, Cornelius J.

AU - Harrison, Thomas S.

AU - Kauffman, Carol A.

AU - Le, Thuy

AU - Miceli, Marisa H.

AU - Mylonakis, Eleftherios

AU - Nguyen, M. Hong

AU - Ostrosky-Zeichner, Luis

AU - Patterson, Thomas F.

AU - Perfect, John R.

AU - Spec, Andrej

AU - Kontoyiannis, Dimitrios P.

AU - Pappas, Peter G.

PY - 2022/6/1

Y1 - 2022/6/1

N2 - Invasive fungal infections continue to increase as at-risk populations expand. The high associated morbidity and mortality with fungal diseases mandate the continued investigation of novel antifungal agents and diagnostic strategies that include surrogate biomarkers. Biologic markers of disease are useful prognostic indicators during clinical care, and their use in place of traditional survival end points may allow for more rapid conduct of clinical trials requiring fewer participants, decreased trial expense, and limited need for long-term follow-up. A number of fungal biomarkers have been developed and extensively evaluated in prospective clinical trials and small series. We examine the evidence for these surrogate biomarkers in this review and provide recommendations for clinicians and regulatory authorities.

AB - Invasive fungal infections continue to increase as at-risk populations expand. The high associated morbidity and mortality with fungal diseases mandate the continued investigation of novel antifungal agents and diagnostic strategies that include surrogate biomarkers. Biologic markers of disease are useful prognostic indicators during clinical care, and their use in place of traditional survival end points may allow for more rapid conduct of clinical trials requiring fewer participants, decreased trial expense, and limited need for long-term follow-up. A number of fungal biomarkers have been developed and extensively evaluated in prospective clinical trials and small series. We examine the evidence for these surrogate biomarkers in this review and provide recommendations for clinicians and regulatory authorities.

KW - diagnosis

KW - fungal infections

KW - mycology

UR - http://www.scopus.com/inward/record.url?scp=85132990016&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85132990016&partnerID=8YFLogxK

U2 - 10.1093/ofid/ofac112

DO - 10.1093/ofid/ofac112

M3 - Review article

AN - SCOPUS:85132990016

SN - 2328-8957

VL - 9

JO - Open Forum Infectious Diseases

JF - Open Forum Infectious Diseases

IS - 6

M1 - ofac112

ER -

Noninvasive Testing and Surrogate Markers in Invasive Fungal Diseases

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this